Literature DB >> 1645826

Serum thymidine kinase in diagnosis and follow-up of the small cell carcinoma of the lung.

V Abbasciano1, L Graziano, D Arcudi, G Felisatti, A R Cavallini, M G Reali, N Calia, S Campi, C Guglielmini.   

Abstract

Serum thymidine-kinase (sTK) was assayed in 48 males affected by small cell carcinoma of the lung (SCCL) at the time of diagnosis. On the same drawing carcinoembryonic antigen (CEA) and beta 2microglobulin (beta 2 microG) were assayed in 19 of these subjects. For staging, the criterion of limited (LD) and extensive (ED) disease was used. Mean sTK and CEA values were above normal range in both the LD and ED groups, while mean beta 2 microG value remained below normal range. Thirty-two patients were subsequently submitted to therapy; sTK was assayed at the end of each treatment cycle. Mean sTK concentrations differed depending on response to therapy. From the data obtained it is concluded that sTK assay is helpful for diagnosis of SCCL; CEA to a lesser extent, above all in association with sTK, and beta microG not at all. sTK assay can also be useful for prognosis and follow-up.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645826     DOI: 10.1007/bf02988568

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  18 in total

1.  Serum thymidine kinase as a prognostic marker in Hodgkin's disease.

Authors:  B Eriksson; H Hagberg; B Glimelius; C Sundström; S Gronowitz; C Källander
Journal:  Acta Radiol Oncol       Date:  1985 Mar-Apr

2.  Regulation of thymidine kinase synthesis in human cells.

Authors:  L J Bello
Journal:  Exp Cell Res       Date:  1974-12       Impact factor: 3.905

Review 3.  Viral-associated and induced enzymes.

Authors:  S Kit
Journal:  Pharmacol Ther B       Date:  1979

4.  Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.

Authors:  H Hagberg; B Glimelius; S Gronowitz; A Killander; C Källander; T Schröder
Journal:  Scand J Haematol       Date:  1984-07

5.  B2-microglobulin, a tumour marker of lymphoproliferative disorder.

Authors:  P L Amlot; M Adinolfi
Journal:  Lancet       Date:  1978-08-26       Impact factor: 79.321

6.  Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.

Authors:  P H Ellims; T Eng Gan; G Medley; M B Van Der Weyden
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

7.  Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers.

Authors:  J S Gronowitz; L Steinholtz; C F Källander; H Hagberg; J Bergh
Journal:  Cancer       Date:  1986-07-01       Impact factor: 6.860

8.  Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.

Authors:  B Simonsson; C F Källander; G Brenning; A Killander; A Ahre; J S Gronowitz
Journal:  Br J Haematol       Date:  1985-10       Impact factor: 6.998

9.  Biological markers and small cell carcinoma of the lung: a clinical evaluation of urinary ribonucleosides.

Authors:  T P Waalkes; M D Abeloff; D S Ettinger; K B Woo; C W Gehrke; K C Kuo; E Borek
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

10.  Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans.

Authors:  J S Gronowitz; F R Källander; H Diderholm; H Hagberg; U Pettersson
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.